Literature DB >> 35505025

Strategies for Improving Photodynamic Therapy Through Pharmacological Modulation of the Immediate Early Stress Response.

Daniel J de Klerk1,2, Mark J de Keijzer1,3, Lionel M Dias1,4, Jordi Heemskerk1, Lianne R de Haan1,2, Tony G Kleijn1,2, Leonardo P Franchi5,6, Michal Heger7,8,9.   

Abstract

Photodynamic therapy (PDT) is a minimally to noninvasive treatment modality that has emerged as a promising alternative to conventional cancer treatments. PDT induces hyperoxidative stress and disrupts cellular homeostasis in photosensitized cancer cells, resulting in cell death and ultimately removal of the tumor. However, various survival pathways can be activated in sublethally afflicted cancer cells following PDT. The acute stress response is one of the known survival pathways in PDT, which is activated by reactive oxygen species and signals via ASK-1 (directly) or via TNFR (indirectly). The acute stress response can activate various other survival pathways that may entail antioxidant, pro-inflammatory, angiogenic, and proteotoxic stress responses that culminate in the cancer cell's ability to cope with redox stress and oxidative damage. This review provides an overview of the immediate early stress response in the context of PDT, mechanisms of activation by PDT, and molecular intervention strategies aimed at inhibiting survival signaling and improving PDT outcome.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ASK-1; Cancer cell survival; Pharmacological intervention; Photosensitizer; Tumor recalcitrance; p38 and JNK, Therapy resistance

Mesh:

Substances:

Year:  2022        PMID: 35505025     DOI: 10.1007/978-1-0716-2099-1_20

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  368 in total

Review 1.  Direct tumor damage mechanisms of photodynamic therapy.

Authors:  Dominika Nowis; Marcin Makowski; Tomasz Stokłosa; Magdalena Legat; Tadeusz Issat; Jakub Gołab
Journal:  Acta Biochim Pol       Date:  2005-06-25       Impact factor: 2.149

2.  Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.

Authors:  Mukund Seshadri; Joseph A Spernyak; Richard Mazurchuk; Susan H Camacho; Allan R Oseroff; Richard T Cheney; David A Bellnier
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

Review 3.  Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver.

Authors:  Megan J Reiniers; Rowan F van Golen; Thomas M van Gulik; Michal Heger
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

4.  Photodynamic Therapy with Liposomal Zinc Phthalocyanine and Tirapazamine Increases Tumor Cell Death via DNA Damage.

Authors:  Mans Broekgaarden; Ruud Weijer; Alebert C van Wijk; Ruud C Cox; Maarten R Egmond; Ron Hoebe; Thomas M van Gulik; Michal Heger
Journal:  J Biomed Nanotechnol       Date:  2017-02       Impact factor: 4.099

Review 5.  Photodynamic therapy for cancer.

Authors:  Dennis E J G J Dolmans; Dai Fukumura; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

Review 6.  Photodynamic therapy.

Authors:  T J Dougherty; C J Gomer; B W Henderson; G Jori; D Kessel; M Korbelik; J Moan; Q Peng
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

7.  Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy.

Authors:  Ruud Weijer; Séverine Clavier; Esther A Zaal; Maud M E Pijls; Robert T van Kooten; Klaas Vermaas; René Leen; Aldo Jongejan; Perry D Moerland; Antoine H C van Kampen; André B P van Kuilenburg; Celia R Berkers; Simone Lemeer; Michal Heger
Journal:  Cell Mol Life Sci       Date:  2016-11-01       Impact factor: 9.261

8.  Inhibition of NF-κB in Tumor Cells Exacerbates Immune Cell Activation Following Photodynamic Therapy.

Authors:  Mans Broekgaarden; Milan Kos; Freek A Jurg; Adriaan A van Beek; Thomas M van Gulik; Michal Heger
Journal:  Int J Mol Sci       Date:  2015-08-21       Impact factor: 5.923

9.  Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy.

Authors:  Ruud Weijer; Mans Broekgaarden; Massis Krekorian; Lindy K Alles; Albert C van Wijk; Claire Mackaaij; Joanne Verheij; Allard C van der Wal; Thomas M van Gulik; Gert Storm; Michal Heger
Journal:  Oncotarget       Date:  2016-01-19

10.  Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells.

Authors:  Ruud Weijer; Mans Broekgaarden; Rowan F van Golen; Esther Bulle; Esther Nieuwenhuis; Aldo Jongejan; Perry D Moerland; Antoine H C van Kampen; Thomas M van Gulik; Michal Heger
Journal:  BMC Cancer       Date:  2015-12-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.